Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...
المؤلفون الرئيسيون: | Chakrabarti, S, Hale, G, Waldmann, H |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2004
|
مواد مشابهة
-
Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
حسب: Watson, C, وآخرون
منشور في: (2004) -
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
حسب: Hale, G, وآخرون
منشور في: (2002) -
The evolving role of alemtuzumab (Campath-1H) in renal transplantation
حسب: Phuong-Thu T Pham, وآخرون
منشور في: (2008-12-01) -
T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
حسب: Hale, G, وآخرون
منشور في: (1988) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
حسب: Clatworthy, MR, وآخرون
منشور في: (2009)